StockNews.com Begins Coverage on Global Cord Blood (NYSE:CO)

Equities research analysts at StockNews.com began coverage on shares of Global Cord Blood (NYSE:CO) in a note issued to investors on Saturday. The brokerage set a “strong-buy” rating on the medical research company’s stock.

Global Cord Blood Trading Up 34.7 %

Shares of CO opened at $2.99 on Friday. Global Cord Blood has a 12-month low of $2.03 and a 12-month high of $5.50. The stock has a market cap of $363.44 million, a P/E ratio of 1.97 and a beta of 0.16. The company has a 50-day moving average of $1.50 and a two-hundred day moving average of $1.40.

About Global Cord Blood

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.